Literature DB >> 15239296

Newborn screening for cystic fibrosis: the practical implications.

Kevin W Southern1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15239296      PMCID： PMC1308801     

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  12 in total

1.  Neonatal screening for cystic fibrosis in Brittany, France: assessment of 10 years' experience and impact on prenatal diagnosis.

Authors:  V Scotet; M de Braekeleer; M Roussey; G Rault; P Parent; M Dagorne; H Journel; A Lemoigne; J P Codet; M Catheline; V David; A Chaventré; I Duguépéroux; C Verlingue; I Quéré; B Mercier; M P Audrézet; C Férec
Journal:  Lancet       Date:  2000-09-02       Impact factor: 79.321

2.  Cystic fibrosis newborn screening and detection of carriers.

Authors:  M Super
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-11       Impact factor: 5.747

Review 3.  Applying CFTR molecular genetics to facilitate the diagnosis of cystic fibrosis through screening.

Authors:  Joseph L Bobadilla; Michael H Farrell; Philip M Farrell
Journal:  Adv Pediatr       Date:  2002

4.  Sweat testing following newborn screening for cystic fibrosis.

Authors:  J Massie; K Gaskin; P Van Asperen; B Wilcken
Journal:  Pediatr Pulmonol       Date:  2000-06

5.  Neonatal screening for cystic fibrosis in the Trent region (UK): two-stage immunoreactive trypsin screening compared with a three-stage protocol with DNA analysis as an intermediate step.

Authors:  R J Pollitt; A Dalton; S Evans; H N Hughes; D Curtis
Journal:  J Med Screen       Date:  1997       Impact factor: 2.136

6.  Dried-blood spot screening for cystic fibrosis in the newborn.

Authors:  J R Crossley; R B Elliott; P A Smith
Journal:  Lancet       Date:  1979-03-03       Impact factor: 79.321

7.  Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group.

Authors:  P M Farrell; M R Kosorok; A Laxova; G Shen; R E Koscik; W T Bruns; M Splaingard; E H Mischler
Journal:  N Engl J Med       Date:  1997-10-02       Impact factor: 91.245

8.  Cystic fibrosis-related deaths in infancy and the effect of newborn screening.

Authors:  I J Doull; H C Ryley; P Weller; M C Goodchild
Journal:  Pediatr Pulmonol       Date:  2001-05

9.  Bronchopulmonary disease in children with cystic fibrosis after early or delayed diagnosis.

Authors:  Philip M Farrell; Zhanhai Li; Michael R Kosorok; Anita Laxova; Christopher G Green; Jannette Collins; Hui-Chuan Lai; Michael J Rock; Mark L Splaingard
Journal:  Am J Respir Crit Care Med       Date:  2003-08-13       Impact factor: 21.405

Review 10.  Newborn screening programmes for cystic fibrosis.

Authors:  Kevin W Southern; James M Littlewood
Journal:  Paediatr Respir Rev       Date:  2003-12       Impact factor: 2.726
View more
  4 in total

1.  The influence of sex, gestational age, birth weight, blood transfusion, and timing of the heel prick on the pancreatitis-associated protein concentration in newborn screening for cystic fibrosis.

Authors:  Annette M M Vernooij-van Langen; J Gerard Loeber; Bert Elvers; Ralf H Triepels; Jos Roefs; Johan J Gille; Sandra Reijntjens; Edward Dompeling; Jeannette E Dankert-Roelse
Journal:  J Inherit Metab Dis       Date:  2012-06-28       Impact factor: 4.982

2.  Newborn screening for cystic fibrosis.

Authors:  T J David
Journal:  J R Soc Med       Date:  2004-05       Impact factor: 18.000

Review 3.  The Role of Information Provision in Economic Evaluations of Newborn Bloodspot Screening: A Systematic Review.

Authors:  Stuart J Wright; Cheryl Jones; Katherine Payne; Nimarta Dharni; Fiona Ulph
Journal:  Appl Health Econ Health Policy       Date:  2015-12       Impact factor: 2.561

4.  Imparting carrier status results detected by universal newborn screening for sickle cell and cystic fibrosis in England: a qualitative study of current practice and policy challenges.

Authors:  Hilda Parker; Nadeem Qureshi; Fiona Ulph; Joe Kai
Journal:  BMC Health Serv Res       Date:  2007-12-13       Impact factor: 2.655
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.